PTC Therapeutics Company Profile (NASDAQ:PTCT)

About PTC Therapeutics (NASDAQ:PTCT)

PTC Therapeutics logoPTC Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation. Ataluren is in clinical development for the treatment of Duchenne muscular dystrophy caused by a nonsense mutation (nmDMD) and cystic fibrosis caused by a nonsense mutation (nmCF). PTC596 is an orally active small molecule that targets tumor stem cell populations by reducing the function, activity and amount of BMI1. RG7916 is an investigational oral therapeutic, which is in two clinical studies: SUNFISH, a trial in childhood onset (Type II/III) spinal muscular atrophy (SMA) patients, and FIREFISH, a trial in infant onset (Type I) SMA patients.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:PTCT
  • CUSIP: N/A
  • Web:
  • Market Cap: $739.51 million
  • Outstanding Shares: 34,316,000
Average Prices:
  • 50 Day Moving Avg: $17.62
  • 200 Day Moving Avg: $13.41
  • 52 Week Range: $4.03 - $21.62
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -9.05
  • P/E Growth: 0.61
Sales & Book Value:
  • Annual Revenue: $90.36 million
  • Price / Sales: 8.18
  • Book Value: $2.94 per share
  • Price / Book: 7.33
  • EBIDTA: ($114,520,000.00)
  • Net Margins: -143.80%
  • Return on Equity: -98.77%
  • Return on Assets: -46.75%
  • Debt-to-Equity Ratio: 0.99%
  • Current Ratio: 5.30%
  • Quick Ratio: 5.27%
  • Average Volume: 806,476 shs.
  • Beta: 1.36
  • Short Ratio: 7.47
Frequently Asked Questions for PTC Therapeutics (NASDAQ:PTCT)

What is PTC Therapeutics' stock symbol?

PTC Therapeutics trades on the NASDAQ under the ticker symbol "PTCT."

How were PTC Therapeutics' earnings last quarter?

PTC Therapeutics, Inc. (NASDAQ:PTCT) announced its earnings results on Monday, May, 8th. The company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.88) by $0.03. The company had revenue of $26.50 million for the quarter, compared to analyst estimates of $27.93 million. PTC Therapeutics had a negative return on equity of 98.77% and a negative net margin of 143.80%. PTC Therapeutics's revenue for the quarter was up 40.2% compared to the same quarter last year. During the same period in the previous year, the firm earned ($1.22) earnings per share. View PTC Therapeutics' Earnings History.

Where is PTC Therapeutics' stock going? Where will PTC Therapeutics' stock price be in 2017?

9 equities research analysts have issued 12-month target prices for PTC Therapeutics' stock. Their predictions range from $7.00 to $25.00. On average, they expect PTC Therapeutics' stock price to reach $15.25 in the next year. View Analyst Ratings for PTC Therapeutics.

What are analysts saying about PTC Therapeutics stock?

Here are some recent quotes from research analysts about PTC Therapeutics stock:

  • 1. According to Zacks Investment Research, "PTC Therapeutics, Inc. is a biopharmaceutical company. It is focused on the discovery and development of orally administered, small-molecule drugs for genetic disorders, oncology and infectious disease. PTC Therapeutics, Inc. is based in South Plainfield, United States. " (7/11/2017)
  • 2. Cowen and Company analysts commented, "PTCT announced 4Q16 results today: Translarna EU sales continue to grow." (3/16/2017)
  • 3. Royal Bank Of Canada analysts commented, "PTCT has announced it has filed its NDA for ataluren with FDA under protest and that the filing has been acknowledged: Recall that the FDA issued a Refuse-to-File letter on 2/23/16. The NDA was initially filed on 1/8/16 and was based on the results of the confirmatory Phase III ACTDMD trial, released 10/15/15, which failed to meet its primary endpoint. We continue to see very little chance that ataluren gets approved in the US, given compelling evidence from multiple randomized clinical trials where this compound failed to meet its primary endpoint. We believe that despite what looks like an improving/lower-threshold FDA environment, the only way this compound can get approval is if it succeeds in a new Phase III trial. Absent that, we believe that the key opportunity to evaluate in PTCT shares are Translarna ex-US sales, which we view as fully valued at current levels. We reiterate our Sector Perform rating on PTCT." (3/6/2017)
  • 4. Jefferies Group LLC analysts commented, "PTCT reported ~$81M Translarna net sales in 2016 (higher vs. our est of $75M) and guided $105-125M for 2017 sales. The topline data for Translarna Ph3 study in CF continues to be expected in late-1Q17 and the company plans to file NDA in DMD over protest in the US. Additional pipeline in SMA and cancer are progressing on-track." (1/10/2017)

Who are some of PTC Therapeutics' key competitors?

Who are PTC Therapeutics' key executives?

PTC Therapeutics' management team includes the folowing people:

  • Michael Schmertzler, Independent Chairman of the Board
  • Stuart W. Peltz Ph.D., Chief Executive Officer, Director
  • Christine Utter, Principal Financial Officer, Principal Accounting Officer, Treasurer
  • Marcio Souza, Chief Operating Officer
  • Neil Almstead Ph.D., Executive Vice President, Research, PharmaceuticalOperations & Technology
  • Mark E. Boulding, Executive Vice President, Chief Legal Officer
  • Tuyen Ong, Chief Medical Officer
  • Mark A. Rothera, Chief Commercial Officer
  • Glenn D. Steele Jr., M.D., Ph.D., Director
  • Dawn Svoronos, Director

Who owns PTC Therapeutics stock?

PTC Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Fisher Asset Management LLC (0.26%), Bank of Montreal Can (0.08%), Nisa Investment Advisors LLC (0.03%) and Creative Planning (0.03%). Company insiders that own PTC Therapeutics stock include Dawn Svoronos, Mark Rothera and Neil Gregory Almstead. View Institutional Ownership Trends for PTC Therapeutics.

Who sold PTC Therapeutics stock? Who is selling PTC Therapeutics stock?

PTC Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can and Creative Planning. View Insider Buying and Selling for PTC Therapeutics.

Who bought PTC Therapeutics stock? Who is buying PTC Therapeutics stock?

PTC Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC. Company insiders that have bought PTC Therapeutics stock in the last two years include Dawn Svoronos and Mark Rothera. View Insider Buying and Selling for PTC Therapeutics.

How do I buy PTC Therapeutics stock?

Shares of PTC Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is PTC Therapeutics' stock price today?

One share of PTC Therapeutics stock can currently be purchased for approximately $21.55.

MarketBeat Community Rating for PTC Therapeutics (NASDAQ PTCT)
Community Ranking:  2.7 out of 5 ( )
Outperform Votes:  252 (Vote Outperform)
Underperform Votes:  223 (Vote Underperform)
Total Votes:  475
MarketBeat's community ratings are surveys of what our community members think about PTC Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for PTC Therapeutics (NASDAQ:PTCT) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 7 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.22)
Consensus Price Target: $15.25 (29.23% downside)

Analysts' Ratings History for PTC Therapeutics (NASDAQ:PTCT)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/20/2017Citigroup Inc.Reiterated RatingBuy$28.00 -> $17.00HighView Rating Details
6/30/2017J P Morgan Chase & CoReiterated RatingNeutral$15.00 -> $21.00LowView Rating Details
5/8/2017Royal Bank Of CanadaSet Price TargetHold$12.00HighView Rating Details
3/22/2017Barclays PLCReiterated RatingEqual Weight$13.00MediumView Rating Details
3/16/2017Cowen and CompanyReiterated RatingHoldHighView Rating Details
3/6/2017Credit Suisse GroupReiterated RatingOutperform -> Positive$25.00N/AView Rating Details
1/10/2017Jefferies Group LLCReiterated RatingHold$12.00N/AView Rating Details
11/11/2016WedbushReiterated RatingNeutral$12.00 -> $7.00N/AView Rating Details
10/3/2016Bank of America CorporationReiterated RatingHold$15.00N/AView Rating Details
4/17/2016Oppenheimer Holdings, Inc.Reiterated RatingBuy$39.00N/AView Rating Details
10/16/2015Roth CapitalReiterated RatingHold$63.00N/AView Rating Details
(Data available from 7/24/2015 forward)


Earnings History for PTC Therapeutics (NASDAQ:PTCT)
Earnings by Quarter for PTC Therapeutics (NASDAQ:PTCT)
Earnings History by Quarter for PTC Therapeutics (NASDAQ PTCT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2017Q1 2017($0.88)($0.85)$27.93 million$26.50 millionViewListenView Earnings Details
3/16/201712/31/2016($1.07)($0.78)$24.69 million$25.20 millionViewN/AView Earnings Details
11/2/2016Q316($1.22)($1.03)$19.76 million$23.00 millionViewN/AView Earnings Details
8/4/2016Q216($1.27)($1.14)$15.24 million$15.40 millionViewN/AView Earnings Details
5/5/2016Q116($1.26)($1.22)$13.74 million$18.90 millionViewN/AView Earnings Details
2/29/2016Q415($1.25)($1.50)$13.04 million$12.70 millionViewListenView Earnings Details
11/9/2015Q315($1.15)($1.27)$9.88 million$9.78 millionViewListenView Earnings Details
7/30/2015Q215($1.20)($1.14)$7.73 million$6.77 millionViewListenView Earnings Details
5/4/2015Q115($1.20)($1.15)$2.97 million$7.50 millionViewN/AView Earnings Details
2/27/2015Q414($0.83)($0.84)$7.99 million$12.70 millionViewListenView Earnings Details
11/6/2014Q314($0.90)($0.93)$1.76 million$1.69 millionViewN/AView Earnings Details
8/7/2014Q214($0.75)($0.86)$1.71 million$1.70 millionViewN/AView Earnings Details
5/6/2014($0.46)($0.58)$10.93 million$9.22 millionViewN/AView Earnings Details
3/6/2014Q413($0.57)($0.75)$6.15 million$4.40 millionViewN/AView Earnings Details
11/14/2013Q3($0.29)($0.19)$7.20 million$16.29 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for PTC Therapeutics (NASDAQ:PTCT)
2017 EPS Consensus Estimate: ($2.93)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.96)($0.70)($0.83)
Q2 20172($0.93)($0.38)($0.66)
Q3 20172($0.89)($0.32)($0.61)
Q4 20172($0.88)($0.80)($0.84)
(Data provided by Zacks Investment Research)


Dividend History for PTC Therapeutics (NASDAQ:PTCT)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for PTC Therapeutics (NASDAQ:PTCT)
Insider Ownership Percentage: 8.10%
Institutional Ownership Percentage: 76.43%
Insider Trades by Quarter for PTC Therapeutics (NASDAQ:PTCT)
Institutional Ownership by Quarter for PTC Therapeutics (NASDAQ:PTCT)
Insider Trades by Quarter for PTC Therapeutics (NASDAQ:PTCT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/23/2017Dawn SvoronosDirectorBuy25,000$13.49$337,250.00View SEC Filing  
1/5/2017Neil Gregory AlmsteadEVPSell78$11.82$921.96View SEC Filing  
3/3/2016Mark RotheraInsiderBuy2,000$6.23$12,460.00View SEC Filing  
7/6/2015David P SouthwellDirectorSell23,604$47.52$1,121,662.08View SEC Filing  
6/18/2015Allan Steven JacobsonDirectorSell5,000$50.13$250,650.00View SEC Filing  
6/9/2015Stuart Walter PeltzCEOSell100,000$54.49$5,449,000.00View SEC Filing  
6/8/2015Mark Elliott BouldingVPSell56,849$55.04$3,128,968.96View SEC Filing  
6/8/2015Richard AldrichDirectorSell7,000$55.66$389,620.00View SEC Filing  
6/8/2015Stuart Walter PeltzCEOSell73,700$54.91$4,046,867.00View SEC Filing  
5/22/2015Shane William Charles KovacsCFOSell82,491$55.41$4,570,826.31View SEC Filing  
4/15/2015Neil Gregory AlmsteadEVPSell9,511$68.65$652,930.15View SEC Filing  
3/23/2015David P SouthwellDirectorSell2,317$69.04$159,965.68View SEC Filing  
3/23/2015Stuart Walter PeltzCEOSell47,200$69.14$3,263,408.00View SEC Filing  
3/20/2015Mark Elliott BouldingVPSell21,142$68.12$1,440,193.04View SEC Filing  
3/18/2015Allan Steven JacobsonDirectorSell16,616$76.00$1,262,816.00View SEC Filing  
3/17/2015Mark RotheraInsiderSell10,700$76.64$820,048.00View SEC Filing  
3/16/2015Michael L KrandaDirectorSell2,500$72.81$182,025.00View SEC Filing  
3/13/2015Robert J SpiegelInsiderSell1,030$75.10$77,353.00View SEC Filing  
3/10/2015Neil Gregory AlmsteadEVPSell79$70.71$5,586.09View SEC Filing  
3/9/2015Stuart Walter PeltzCEOSell47,201$70.74$3,338,998.74View SEC Filing  
2/25/2015Mark RotheraInsiderSell35,000$68.01$2,380,350.00View SEC Filing  
2/24/2015Mark RotheraInsiderSell1,000$67.70$67,700.00View SEC Filing  
2/23/2015Mark RotheraInsiderSell23,000$65.40$1,504,200.00View SEC Filing  
1/21/2015Neil Gregory AlmsteadEVPSell26,096$60.26$1,572,544.96View SEC Filing  
1/20/2015Mark RotheraInsiderSell3,000$60.02$180,060.00View SEC Filing  
1/16/2015Mark RotheraInsiderSell2,300$58.67$134,941.00View SEC Filing  
1/15/2015Claudia De Oliveira Ri HirawatPresidentSell2,149$57.19$122,901.31View SEC Filing  
1/14/2015Mark RotheraInsiderSell9,700$58.04$562,988.00View SEC Filing  
12/15/2014Claudia De Oliveira Ri HirawatPresidentSell2,173$55.24$120,036.52View SEC Filing  
11/17/2014Claudia De Oliveira Ri HirawatPresidentSell2,173$39.78$86,441.94View SEC Filing  
10/15/2014Claudia De Oliveira Ri HirawatPresidentSell45,661$36.15$1,650,645.15View SEC Filing  
10/10/2014Claudia De Oliveira Ri HirawatPresidentSell43,489$36.18$1,573,432.02View SEC Filing  
10/1/2014Stuart Walter PeltzCEOSell41,501$42.65$1,770,017.65View SEC Filing  
9/26/2014Mark RotheraInsiderSell16,000$44.63$714,080.00View SEC Filing  
9/18/2014Allan Steven JacobsonDirectorSell2,000$40.16$80,320.00View SEC Filing  
9/15/2014Mark RotheraInsiderSell8,000$36.24$289,920.00View SEC Filing  
5/22/2014Shane William Charles KovacsCFOSell1,650$14.74$24,321.00View SEC Filing  
3/24/2014Stuart Walter PeltzCEOSell25,487$29.86$761,041.82View SEC Filing  
3/21/2014Claudia De Oliveira Ri HirawatPresidentSell15,320$29.61$453,625.20View SEC Filing  
3/21/2014David SouthwellDirectorSell2,317$30.93$71,664.81View SEC Filing  
3/20/2014Mark Elliott BouldingVPSell10,049$30.96$311,117.04View SEC Filing  
3/19/2014Neil Gregory AlmsteadVPSell10,859$31.91$346,510.69View SEC Filing  
3/18/2014Allan Steven JacobsonDirectorSell7,616$31.18$237,466.88View SEC Filing  
3/14/2014Michael KrandaDirectorSell1,186$31.02$36,789.72View SEC Filing  
3/13/2014Robert SpiegelInsiderSell1,186$31.75$37,655.50View SEC Filing  
3/7/2014Stuart Walter PeltzCEOSell27,414$29.91$819,952.74View SEC Filing  
12/17/2013Hbm Healthcare Investments (Camajor shareholderSell66,667$19.08$1,272,006.36View SEC Filing  
6/25/2013Adam KoppelDirectorBuy1,250,000$15.00$18,750,000.00View SEC Filing  
6/25/2013Hbm Healthcare Investments (CaMajor ShareholderBuy666,676$15.00$10,000,140.00View SEC Filing  
6/25/2013Mark RotheraInsiderBuy25,000$15.00$375,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for PTC Therapeutics (NASDAQ:PTCT)
Latest Headlines for PTC Therapeutics (NASDAQ:PTCT)
DateHeadline logoPTC Therapeutics Announces Promotion of Dr. Joseph McIntosh to Senior Vice President and Head of Clinical Development - July 24 at 4:34 PM logoPTC Therapeutics, Inc. (NASDAQ:PTCT) Rating Reiterated by Citigroup Inc. - July 20 at 10:35 AM logoPTC Therapeutics (PTCT) Releases Results from ACT DMD in The ... - - July 20 at 6:40 AM logoZacks: Brokerages Expect PTC Therapeutics, Inc. (NASDAQ:PTCT) to Announce -$0.97 Earnings Per Share - July 19 at 11:34 AM logoPTC Therapeutics (PTCT) Releases Results from ACT DMD in The Lancet - July 19 at 5:31 AM logoPTC Therapeutics Announces Publication of Data from ACT DMD in The Lancet - July 19 at 5:31 AM logoHow These Biotechs Are Dodging Payor Pushback In Muscular Dystrophy - July 18 at 7:33 AM logoPTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Consensus Recommendation of "Hold" from Analysts - July 14 at 10:52 PM logoHere's Why PTC Therapeutics, Inc. Popped 45.2% in June - July 8 at 1:46 PM logoHere's Why PTC Therapeutics, Inc. Popped 45.2% in June - July 8 at 7:00 AM logoPTC Therapeutics (PTCT) Presents Phase 2 SUNFISH Trial Evaluating Oral RG7916 from Spinal Muscular Atrophy ... - - July 4 at 6:38 AM logoPreliminary Phase 2 Data from Spinal Muscular Atrophy Program Presented at CureSMA Conference - July 2 at 6:40 AM logoPTC Therapeutics, Inc. (PTCT) Lowered to Sell at Zacks Investment Research - July 1 at 7:23 AM logoCompany Spotlight: PTC Therapeutics - July 1 at 6:44 AM logoPTC Therapeutics' (PTCT) Neutral Rating Reiterated at J P Morgan Chase & Co - June 30 at 2:53 PM logoPTC Therapeutics: The Star Is Rising - June 27 at 7:27 PM logoPTC Therapeutics (PTCT) Announces New Analyses of Translarna Data from ACT DMD Presented at EPNS - June 23 at 8:05 PM logoPTC Therapeutics (PTCT) Announces New Analyses of Translarna Data from ACT DMD Presented at EPNS - - June 23 at 9:18 AM logoETFs with exposure to PTC Therapeutics, Inc. : June 22, 2017 - June 23 at 9:18 AM logoNew Analyses of Translarna™ (ataluren) Data from ACT DMD Presented at the 12th Annual European Pediatric Neurology Society Congress - June 22 at 8:41 AM logoPTC Therapeutics, Inc. (PTCT) Receives Average Recommendation of "Hold" from Brokerages - June 19 at 10:48 PM logoETFs with exposure to PTC Therapeutics, Inc. : June 12, 2017 - June 12 at 6:59 PM logoPTC Therapeutics, Inc. :PTCT-US: Earnings Analysis: Q1, 2017 By the Numbers : June 9, 2017 - June 9 at 3:46 PM logoToday's Research Reports on Stocks to Watch: PTC Therapeutics and Organovo - June 8 at 8:58 AM logoPTC Therapeutics, Inc. (PTCT) Receives Buy Rating from Citigroup Inc - June 7 at 12:22 PM logoPTC Therapeutics Announces FDA Advisory Committee Meeting for Ataluren for the Treatment of Nonsense Mutation Dystrophinopathy - June 6 at 8:12 PM logoPTC Therapeutics (PTCT) Names Marcio Souza Chief Operating Officer - - June 6 at 12:58 AM logoPTC Therapeutics Moves On Old Report - Benzinga - June 1 at 8:34 PM logoDawn Svoronos Purchases 25,000 Shares of PTC Therapeutics, Inc. (PTCT) Stock - May 24 at 7:41 PM logoNew Analysis of ACT DMD Placebo Data on Corticosteroids Presented at International Society for Pharmacoeconomics ... - PR Newswire (press release) - May 24 at 7:40 PM logoPTC Therapeutics, Inc. (PTCT) Given Average Rating of "Hold" by Analysts - May 23 at 8:22 PM logoNew Analysis of ACT DMD Placebo Data on Corticosteroids Presented at International Society for Pharmacoeconomics and Outcomes Research 22nd Annual International Meeting - May 23 at 9:46 AM logoPTC Therapeutics, Inc. (PTCT) Downgraded by Zacks Investment Research - May 11 at 8:24 AM logoPTC Therapeutics, Inc. (PTCT) Given a $12.00 Price Target at Royal Bank of Canada - May 9 at 6:52 PM logoToday's Research Reports on Stocks to Watch: Horizon Pharma and PTC Therapeutics - May 9 at 10:59 AM logoPTC Therapeutics, Inc. (PTCT) Announces Quarterly Earnings Results, Beats Estimates By $0.18 EPS - May 8 at 8:16 PM logoWhy PTC Therapeutics Stock Is Sinking Today - May 8 at 6:43 PM logoInvestor Network: PTC Therapeutics, Inc. to Host Earnings Call - May 8 at 11:55 AM logoPTC Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update - May 8 at 11:55 AM logo[$$] PTC Expects Net Price of $35,000 Annually Per Patient for Emflaza - May 8 at 11:55 AM logoThis rare disease drug’s price tag was reduced from $89,000-a-year. But that may not be enough - May 8 at 11:55 AM logoPTC Therapeutics reports 1Q loss - May 8 at 7:49 AM logo5 Stocks with Earnings Acceleration to Buy Now - May 2 at 5:11 PM logoPTC Therapeutics (PTCT) Earning Somewhat Positive News Coverage, Study Finds - May 2 at 11:40 AM logoPTC Therapeutics, Inc. (PTCT) Given Average Recommendation of "Hold" by Analysts - April 29 at 1:22 AM logoPTC Therapeutics (PTCT) Given News Sentiment Score of 0.20 - April 27 at 10:38 PM logoSomewhat Critical Press Coverage Likely to Affect PTC Therapeutics (PTCT) Share Price - April 24 at 6:28 PM logoPTC Therapeutics (PTCT) Given Coverage Optimism Score of 0.04 - April 22 at 12:59 AM logoPTC Therapeutics, Inc. (PTCT) Sees Significant Growth in Short Interest - April 21 at 11:01 AM logoPTC Therapeutics Completes Acquisition of Emflaza™ for the Treatment of Duchenne Muscular Dystrophy in the U.S. - PR Newswire (press release) - April 21 at 8:48 AM



PTC Therapeutics (PTCT) Chart for Monday, July, 24, 2017

This page was last updated on 7/24/2017 by Staff